Edgewood Oncology Emerges From Stealth with $20 Million in Series A Financing to Advance BTX-A51 in Patients with Hematologic Malignancies and Genetically-Defined Solid Tumors
BROOKLINE, Mass.--(BUSINESS WIRE)--Mar 25, 2024--
Source: valdostadailytimes.com